The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Enabling a new era in minimally invasive obesity treatment across Europe
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Poviztra is a second brand of Wegovy
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
